Finzati - Logo
GTBP logo

GT Biopharma, Inc.

GTBPBiotechnology
$0.24
-0.01 (-4.52%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$9.34M
Growth
-100.0%
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Healthy liquidity · 3.5Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 16, 2026, 12:18 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.24
Change-4.52%
Market Cap$9.34M
52W Range0.26 - 1.53
Beta0.90
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio3.50
Quick Ratio3.50
Revenue 5Y-100.00%

Investment DNA

How strong this company looks for long-term investors

47
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
70/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
95/100
Why this score
Manageable debt level · 0Healthy liquidity · 3.5Weak profitability
Analyst view
No analyst data available now.

Company Overview

IPO: 3/27/2018
Industry: Biotechnology
P/B i: 0.75
Debt / Equity i: 0.00
Operating Margin: 0.00%
Net Margin: 0.00%
ROE i: -
ROIC: -

Financial Health

Score14 / 20
Debt / Equity: 0.00
Current Ratio: 3.50
Quick Ratio: 3.50
Status: Good

Insider Transactions

Recent executive and insider activity

1 high-volume insider sell detected
Kramer Hilary
Transaction: 09/04/2025
BUY
Change
+31,250
Price
$1.33
Filing
09/08/2025
Type
BUY
CASAMENTO CHARLES J
Transaction: 09/04/2025
BUY
Change
+62,500
Price
$1.33
Filing
09/08/2025
Type
BUY
URBAN ALAN LOUIS
Transaction: 09/04/2025
BUY
Change
+50,000
Price
$1.33
Filing
09/08/2025
Type
BUY